Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera

Vaccines and antibody-based therapeutics like convalescent-phase plasma therapy are premised upon inducing or transferring neutralizing antibodies that inhibit SARS-CoV-2 entry into cells. Virus neutralization assays (VNAs) for measuring neutralizing antibody titers (NATs) are an essential part of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kasopefoluwa Y. Oguntuyo, Christian S. Stevens, Chuan Tien Hung, Satoshi Ikegame, Joshua A. Acklin, Shreyas S. Kowdle, Jillian C. Carmichael, Hsin-Ping Chiu, Kristopher D. Azarm, Griffin D. Haas, Fatima Amanat, Jéromine Klingler, Ian Baine, Suzanne Arinsburg, Juan C. Bandres, Mohammed N. A. Siddiquey, Robert M. Schilke, Matthew D. Woolard, Hongbo Zhang, Andrew J. Duty, Thomas A. Kraus, Thomas M. Moran, Domenico Tortorella, Jean K. Lim, Andrea V. Gamarnik, Catarina E. Hioe, Susan Zolla-Pazner, Stanimir S. Ivanov, Jeremy P. Kamil, Florian Krammer, Benhur Lee
Formato: article
Lenguaje:EN
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://doaj.org/article/9f425d57749f4d2aabcd8c8d41ea0f24
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares